Dapsone treatment is efficient against persistent cutaneous and gastrointestinal symptoms in children with Henoch-Schönlein purpura
Language English Country Czech Republic Media print-electronic
Document type Case Reports, Journal Article
PubMed
29097818
DOI
10.5507/bp.2017.044
Knihovny.cz E-resources
- Keywords
- Henoch-Schönlein purpura, atypical bacteria, children, dapsone,
- MeSH
- Skin Diseases, Bacterial drug therapy MeSH
- Chlamydophila pneumoniae MeSH
- Dapsone therapeutic use MeSH
- Child MeSH
- Gastrointestinal Diseases drug therapy MeSH
- IgA Vasculitis complications MeSH
- Chlamydophila Infections complications MeSH
- Humans MeSH
- Adolescent MeSH
- Mycoplasma pneumoniae MeSH
- Pneumonia, Mycoplasma complications MeSH
- Child, Preschool MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Child, Preschool MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Dapsone MeSH
BACKGROUND: Henoch-Schönlein purpura (HSP) is a systemic disorder characterized by leukocytoclastic vasculitis involving the capillaries and by the deposition of IgA immune complexes. An association between HSP and atypical bacteria is uncommon in children. METHODS AND RESULTS: Here we report three cases of children, aged 5, 4 and 16 years, who were diagnosed with HSP associated with Mycoplasma pneumoniae or Chlamydia pneumoniae infection. In all presented cases, persistent cutaneous manifestations and abdominal pain were resistant to antibiotics and corticosteroids, but resolved during 48 h after the introduction of dapsone. No adverse effects of treatment were observed. CONCLUSION: Dapsone, a sulphone with an anti-inflammatory activity, showed remarkable therapeutic efficacy against rash and gastrointestinal symptoms in children with HSP. Its administration should be considered particularly in persistent cutaneous form of HSP.
References provided by Crossref.org